Takeda gives Affymax $10M milestone payment for anemia therapy

08/10/2011 | Forbes

Takeda Pharmaceutical paid a $10 million milestone fee to Affymax after the FDA accepted a marketing application for anemia drug candidate peginesatide. The companies aim to co-promote the drug to anemic patients with chronic renal failure.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN